Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00878189 · ClinicalTrials.gov registry record · Phase 1

A Trial In Patients With Advanced Cancer And Leukemia

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
72
Enrollment target

NCT00878189: Completed Phase 1 study, sponsored by Pfizer.

NCT00878189 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00878189, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
72 participants
Enrollment target

Study Summary

This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

Primary Outcome

Any DLT event attributable to PF-03084014 during Cycle 1: non-hematologic toxicities \>= Grade 3 despite optimal care; treatment delay \>=7 days or unable to deliver at least 80% of planned dose due to treatment-related toxicities; Grade 4 neutropenia \>7 days; febrile neutropenia; neutropenic infection; Grade \>=3 thrombocytopenia with bleeding

Interventions

  • DRUG PF-03084014

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2009-06-25
Est. Completion 2016-11-22
Phase Phase 1
Pfizer

1,845 total trials

What the finished NCT00878189 record still lists

NCT00878189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).

The record links to 0 conditions, and to 1 intervention - of which PF-03084014 is the first listed.

NCT00878189 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00878189 about?

NCT00878189 is a clinical study titled "A Trial In Patients With Advanced Cancer And Leukemia". This is a phase 1, dose escalating study to determine the safety of PF-03084014 in patients with advanced cancer and leukemia

What is the current status of trial NCT00878189?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2009-06-25. Estimated completion is 2016-11-22.

What interventions are being tested in trial NCT00878189?

The interventions under investigation include: PF-03084014 (DRUG).

Who is sponsoring clinical trial NCT00878189?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00878189's enrollment target sits among peer trials

72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00878189, the US trial registry maintained by the National Library of Medicine. NCT00878189 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.